Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a note issued to investors on Sunday. The firm set a “hold” rating on the medical research company’s stock.

CTSO has been the topic of several other research reports. HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Wednesday, August 14th. EF Hutton Acquisition Co. I raised Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $0.74 on Friday. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $2.15. The company has a current ratio of 2.12, a quick ratio of 1.71 and a debt-to-equity ratio of 0.82. The business’s 50 day moving average is $1.13 and its two-hundred day moving average is $1.01. The company has a market capitalization of $40.28 million, a P/E ratio of -1.40 and a beta of 0.56.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $9.89 million during the quarter, compared to the consensus estimate of $9.73 million. Cytosorbents had a negative return on equity of 131.84% and a negative net margin of 68.70%. During the same period last year, the company earned ($0.14) EPS. Analysts expect that Cytosorbents will post -0.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Atomi Financial Group Inc. acquired a new position in shares of Cytosorbents during the third quarter worth about $51,000. CM Management LLC raised its stake in Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after buying an additional 25,000 shares in the last quarter. Sargent Investment Group LLC increased its holdings in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares during the last quarter. Finally, Avenir Corp raised its position in shares of Cytosorbents by 4.0% during the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after acquiring an additional 121,294 shares in the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.